Sanofi and GlaxoSmithKline will apply for regulatory approval of their long-awaited Covid-19 vaccine as a primary jab and booster, after reporting an overall efficacy rate of 57.9 per cent.
賽諾菲(Sanofi)和葛蘭素史克(GlaxoSmithKline)將申請監管機構批準它們期待已久的新冠疫苗作為基礎劑和加強針，此前兩家公司報告的總有效性為57.9%。
您已閱讀8%（274字），剩余92%（3120字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。